Sorafenib and hepatocellular carcinoma: is alpha-fetoprotein a biomarker predictive of tumor biology and primary resistance?
| Autor: | Francesca Negri, Enrico Maria Silini, Letizia Gnetti, Giuseppe Pedrazzi, Camillo Porta |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Sorafenib
Oncology Cancer Research medicine.medical_specialty Carcinoma Hepatocellular Angiogenesis Drug Resistance Antineoplastic Agents Internal medicine medicine Biomarkers Tumor Humans neoplasms Tumor marker Tumor biology business.industry digestive oral and skin physiology Liver Neoplasms General Medicine medicine.disease Prognosis digestive system diseases Clinical trial Hepatocellular carcinoma embryonic structures Biomarker (medicine) alpha-Fetoproteins Alpha-fetoprotein business medicine.drug |
| Zdroj: | Future oncology (London, England). 17(27) |
| ISSN: | 1744-8301 |
| Popis: | Lay abstract Alpha-fetoprotein (AFP) is a plasma protein commonly used as a tumor marker for hepatocellular carcinoma. Sorafenib is a targeted therapy used to block the growth of cancer cells in several ways. It affects various proteins on the surface of cancer cells as well as targets inside the cell. Some of these targets are involved in tumor angiogenesis (growth of new blood vessels). In the present analysis, elevated AFP plasma levels before starting sorafenib therapy were correlated with inferior survival compared with patients with low AFP levels, thus suggesting a possible role of AFP in resistance to sorafenib therapy. Using a specific antibody, the authors also studied the expression on cancer cells of VEGFR2, which is a protein involved in angiogenesis and one of the targets of sorafenib. No correlation was found between AFP level and VEGFR2 expression. The underlying mechanisms involved in resistance to sorafenib therapy still need to be clarified and deserve further studies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|